JP2009523456A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523456A5
JP2009523456A5 JP2008551611A JP2008551611A JP2009523456A5 JP 2009523456 A5 JP2009523456 A5 JP 2009523456A5 JP 2008551611 A JP2008551611 A JP 2008551611A JP 2008551611 A JP2008551611 A JP 2008551611A JP 2009523456 A5 JP2009523456 A5 JP 2009523456A5
Authority
JP
Japan
Prior art keywords
treating
drug
vasopressin
subject
gene sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008551611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/000111 external-priority patent/WO2007085087A1/en
Publication of JP2009523456A publication Critical patent/JP2009523456A/ja
Publication of JP2009523456A5 publication Critical patent/JP2009523456A5/ja
Pending legal-status Critical Current

Links

JP2008551611A 2006-01-24 2007-01-24 重篤な被検体の被検体結果の指標としてのバソプレシン経路多型 Pending JP2009523456A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76132806P 2006-01-24 2006-01-24
US79515706P 2006-04-27 2006-04-27
PCT/CA2007/000111 WO2007085087A1 (en) 2006-01-24 2007-01-24 Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects

Publications (2)

Publication Number Publication Date
JP2009523456A JP2009523456A (ja) 2009-06-25
JP2009523456A5 true JP2009523456A5 (enExample) 2010-03-11

Family

ID=38308805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551611A Pending JP2009523456A (ja) 2006-01-24 2007-01-24 重篤な被検体の被検体結果の指標としてのバソプレシン経路多型

Country Status (6)

Country Link
EP (1) EP1984546A4 (enExample)
JP (1) JP2009523456A (enExample)
AU (1) AU2007209725A1 (enExample)
CA (1) CA2638773A1 (enExample)
MX (1) MX2008009654A (enExample)
WO (1) WO2007085087A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033720A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Mastoparan for the treatment of diseases
CA2699100A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
RU2010114013A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение нейротрофического фактора для холинергических нейронов сетчатки (nfrcn) и хорионического гонадотропина бета (109-145) в качестве терапевтических средств
KR20100057052A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
WO2009033820A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CN102686728B (zh) 2009-06-29 2018-09-18 卢米耐克斯公司 具有发夹构象的嵌合引物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011548A1 (en) * 1988-05-20 1989-11-30 Cetus Corporation Immobilized sequence-specific probes
US6727063B1 (en) * 1999-09-10 2004-04-27 Millennium Pharmaceuticals, Inc. Single nucleotide polymorphisms in genes
CA2498509A1 (en) * 2002-05-17 2003-11-27 Riken Method of detecting gene polymorphism
US20040033582A1 (en) * 2002-06-03 2004-02-19 Manling-Ma Edmonds Human single nucleotide polymorphisms
EP1618208B1 (en) * 2003-03-19 2010-04-28 The University of British Columbia Plasminogen activator inhibitor-1 (pai-1) haplotypes useful as indicators of patient outcome
WO2005038462A1 (en) * 2003-10-21 2005-04-28 Suntory Limited Method for prognostic evaluation of carcinoma using anti-p-lap antibody
AU2005219473A1 (en) * 2004-03-04 2005-09-15 The University Of British Columbia Toll-like receptor 2 (TLR-2) haplotypes predict outcome of patients
WO2005085273A1 (en) * 2004-03-04 2005-09-15 The University Of British Columbia Thrombomodulin (thbd) haplotypes predict outcome of patients
CA2479968A1 (en) * 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome

Similar Documents

Publication Publication Date Title
JP2011511805A5 (enExample)
JP2009523456A5 (enExample)
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
JP2009513660A5 (enExample)
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
JP2008245635A5 (enExample)
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
JP2011525990A5 (enExample)
JP2007517055A5 (enExample)
MY153198A (en) Inhibitors of protein aggregation
CL2007001132A1 (es) Compuestos derivados de purina sustituida con otros sistemas heterociclicos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
EP2240136A4 (en) DEVICE FOR TREATING GASTROÖSOPHAGEAL REFLUX (GERD) AND ADIPOSITAS
NO20092398L (no) Krystallinske former av solvatisert ilaprazol
JP2015504870A5 (enExample)
EP2164505A4 (en) TREATMENT OF CHRONIC LUNG DISEASE
JP2013539454A5 (enExample)
NO20084458L (no) IL-8-reseptorantagonister
JP2016538270A5 (enExample)
JP2009506080A5 (enExample)
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
JP2008013542A5 (enExample)
EP2140882A4 (en) MEDICINE FOR THE TREATMENT OF LUNG DISEASES
WO2008112903A3 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
JP2009515556A5 (enExample)
JP2008534513A5 (enExample)